Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus

Atherosclerosis

Volumn 139, Issue 2, 1998, Pages 341-349

  MacKness, Bharti ^a   MacKness, Michael I ^a   Arrol, Sharon ^a   Turkie, Wajdi ^b   Julier, Kay ^a   Abuasha, Bashir ^a   Miller, John E ^c   Boulton, Andrew J M ^a   Durrington, Paul N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Bridge Medical Centre Cheadle Hulme   (United Kingdom)

Author keywords

Lipoproteins; Non insulin dependent diabetes mellitus; Paraoxonase; Polymorphism

Indexed keywords

ARYLESTERASE;

AMINO ACID SUBSTITUTION; ARTERY WALL; ARTICLE; DETOXIFICATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LIPID OXIDATION; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, TYPE 2; ESTERASES; FEMALE; GENOTYPE; HUMANS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; POLYMORPHISM, GENETIC; REFERENCE VALUES;

EID: 0031859456     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00095-1     Document Type: Article

References (27)

1. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med. 320:1989;915.
2. Mackness M.I., Durrington P.N. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243.
3. Mackness M.I., Abbott C.A., Arrol S., Durrington P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 294:1993;829.
4. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:1991;152.
5. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129.
6. Watson A.D., Berliner J.A., Hama S.Y.et al. Protective effect of high density lipoprotein associated paraoxonase - inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest. 96:1995;2882.
7. Mackness MI. Commentary, Review: 'A'-esterases - enzymes looking for a role. Biochem Pharmacol 1989;38:385.
8. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxon hydrolysing activity in the serum of patients after myocardial infarction. Clin Chem. 32:1986;671.
9. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J.M., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 15:1995;1812.
10. Patel B.N., Mackness M.I., Harty D.W., Arrol S., Boot-Handford R.P., Durrington P.N. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta. 1035:1990;113.
11. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmacogenetics of Drug Metabolism. New York: Pergamon, 1992:51.
12. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 7:1996;69.
13. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Drug Metab Dispos. 19:1991;100.
14. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 52:1993;598.
15. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet. 3:1993;73.
16. Blatter-Garin M.-C., James R.W., Dussoix P.et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. J Clin Invest. 99:1997;62.
17. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997;122:265.
18. Saha N., Roy A.C., Teo S.H., Tay J.S.H., Ratnam S.S. Influence of serum paraoxonase polymorphism on serum lipids and lipoproteins. Clin Genet. 40:1991;277.
19. Hegele R.A., Brunt J.H., Connelly P.W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Throm Vasc Biol. 15:1995;89.
20. Ruiz J., Blanché H., James R.W., Blatter-Garin M.-C.et al. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869.
21. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 96:1995;3005.
22. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Throm Vasc Biol. 17:1997;1067.
23. Anikainen M., Martomäki S., Syränne M.et al. The Gln-Arg 191 polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. 98:1996;883.
24. Herrmann S.M., Blanc H., Poirier O.et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 126:1996;299.
25. Mackness M.I., Arrol S., Mackness B., Durrington P.N. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet. 349:1997;851.
26. World Health Organisation Expert Committee on Diabetes Mellitus, 2nd Report. WHO Technical Report Series No. 646. Geneva: WHO, 1980.
27. Mackness MI, Durrington PN. Lipoprotein separation and analysis for clinical studies. In: Converse CA, Skinner ER, editors. Lipoprotein Analysis: a Practical Approach. Oxford: IRL Press, 1992:1.